Nanomicro 纳微科技
9 significant filings since 31 May 2026: 6 on share issue, 1 on freeze lifted and 1 on major holder selling, and 1 other kind. The latest, on 22 Sep 2026: 华泰联合证券有限责任公司关于苏州纳微科技股份有限公司向特定对象发行股票之发行保荐书. On 9 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 102.00% to 137.00% from the same period a year earlier.
自 31 May 2026 起有 9 份重大公告：share issue 6 份、freeze lifted 1 份、major holder selling 1 份，另有 1 类。最新一份（22 Sep 2026）：华泰联合证券有限责任公司关于苏州纳微科技股份有限公司向特定对象发行股票之发行保荐书。9 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 102.00% 至 137.00%。
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥190亿 | ¥63亿 | 23rd highest of 158 · 158 家中第 23 高 | |
| Trailing P/E 市盈率 | 90.6x | 38.6x | 21st highest of 112 · 112 家中第 21 高 | |
| P/B 市净率 | 9.1x | 2.5x | 16th highest of 157 · 157 家中第 16 高 | |
| Revenue Growth 营收增速 | 37.3% | 1.6% | 21st highest of 156 · 156 家中第 21 高 | |
| Profit Growth 净利增速 | 116.1% | 1.9% | 28th highest of 158 · 158 家中第 28 高 | |
| Gross Margin 毛利率 | 71.5% | 50.2% | 36th highest of 155 · 155 家中第 36 高 | |
| Net Margin 净利率 | 24.8% | 9.8% | 19th highest of 157 · 157 家中第 19 高 | |
| Return on Equity 净资产收益率 | 6.8% | 3.1% | 30th highest of 157 · 157 家中第 30 高 | |
| Debt to Assets 资产负债率 | 12.1% | 28.0% | 25th lowest of 158 · 158 家中第 25 低 | |
| Grade Score 评级得分 | 71 | 51 | 15th highest of 157 · 157 家中第 15 高 |
Statement figures are for the period to 30 Jun 2026, filed by 158 of 158 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，158 家同业中 158 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Beone Medicines 百济神州 | ¥3,979亿 | 92.9x | 11.2x | 26.8% | 14.7% | 9.9% | B |
| Hengrui Pharma 恒瑞医药 | ¥2,977亿 | 38.5x | 4.6x | -1.9% | 28.9% | 8.0% | C |
| Haisco Pharmaceutical Group 海思科 | ¥699亿 | 73.7x | 14.3x | 54.7% | 27.5% | 18.3% | B |
| CSPC Innovation Pharmaceutical 石药创新 | ¥620亿 | 60.6x | 15.8x | 208.7% | 47.9% | 38.2% | B |
| Sichuan Kelun Pharmaceutical 科伦药业 | ¥618亿 | 33.8x | 2.5x | -2.7% | 16.1% | 4.6% | C |
| Fosun Pharma 复星医药 | ¥610亿 | 18.0x | 1.3x | 4.8% | 10.5% | 3.5% | D |
| Innocare 诺诚健华 | ¥528亿 | 57.5x | 6.9x | 55.5% | 21.1% | 3.2% | C |
| Allist 艾力斯 | ¥469亿 | 17.5x | 5.5x | 39.9% | 46.4% | 19.7% | B |
| Huadong Medicine 华东医药 | ¥457亿 | 13.2x | 1.8x | 1.8% | 8.3% | 7.3% | C |
| Shenzhen Salubris Pharmaceuticals 信立泰 | ¥337亿 | 50.0x | 3.9x | 16.3% | 15.8% | 4.3% | C |
| Humanwell Healthcare ST人福 | ¥307亿 | 15.1x | 1.6x | -0.0% | 14.0% | 6.8% | C |
| Apeloa Pharmaceutical 普洛药业 | ¥293亿 | 34.5x | 4.5x | -11.4% | 10.8% | 8.1% | D |
| Zelgen 泽璟制药 | ¥288亿 | 52.5x | 16.8x | 220.9% | 53.1% | 45.7% | B |
| Dizal Pharmaceutical 迪哲医药 | ¥263亿 | — | 23.2x | 47.2% | -40.8% | -17.2% | D |
| Nanomicro 纳微科技 | ¥190亿 | 90.6x | 9.1x | 37.3% | 24.8% | 6.8% | B |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。